Adia Med sells 30% stake in Adia Labs to Live Oak Health for $1.5 million

• Adia Med agreed to sell 30% of subsidiary Adia Labs to Live Oak Health (QCM Biologics) for USD 1.5 million.
• Consideration set at USD 1 million cash, USD 500,000 promissory note bearing 7% interest with interest-only monthly payments for 48 months.
• Transaction closing tied to receipt of the USD 1 million wire transfer, required by Sept. 30, 2026 unless extended.
• Buyer received an option to buy up to an additional 10% at USD 50,000 per unit through 5 p.m. ET on Sept. 30, 2028.
• Voting control resets to 50-50 between the parties at closing despite 70-30 economic ownership, remaining equal if the option is exercised.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adia Med Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-007632), on October 06, 2026, and is solely responsible for the information contained therein.